Statin Adherence: Does Gender Matter?

Karen M Goldstein1,2, Leah L Zullig3,4, Lori A Bastian5,6

  • 1Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC, 27705, USA. Karen.goldstein@duke.edu.

Insights

Women face unique challenges with statin adherence, leading to cardiovascular disease (CVD) disparities. Addressing gender-specific factors is crucial for improving statin use and outcomes in women.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Health Disparities

Background:

  • Cardiovascular disease (CVD) remains a leading cause of death in the USA.
  • Statins have reduced cardiovascular mortality, but their benefits are not equally distributed across genders.
  • Women are less likely to use statins and achieve LDL goals compared to men.

Purpose of the Study:

  • To investigate gender-based differences in the provision and adherence to statin therapy.
  • To identify factors contributing to statin adherence disparities between men and women.

Main Methods:

  • Review of existing literature on gender differences in statin use and adherence.
  • Analysis of provider and patient-level factors influencing statin adherence.
  • Exploration of psychosocial and medication intolerance factors.

Main Results:

  • Women exhibit lower adherence rates to statins compared to men.
  • Factors contributing to non-adherence include lower awareness of CVD risk, higher statin intolerance, and caregiving responsibilities.
  • Inadequate gender-specific analyses in clinical trials limit understanding.

Conclusions:

  • Gender-based disparities in statin adherence are influenced by provider, psychosocial, and intolerance factors.
  • Interventions to improve statin adherence must consider women's specific challenges, including age at CVD risk onset and caregiving roles.
  • Addressing these disparities is essential for equitable CVD prevention and treatment outcomes.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
359
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
295
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
399
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K